OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 14, 2021
How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.
December 15, 2020
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
December 11, 2020
Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.
December 03, 2020
How technology can maximize use of manufacturer copay and patient assistance programs.
November 02, 2020
Rasim Shah talks about how the application of AI to Pricing and Reimbursement can dramatically free up time spent on crunching datasets, modeling scenarios, and building price predictions.
October 30, 2020
The second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
October 29, 2020
Ira Studin takes a look at how pharma manufacturers can address extreme pricing and build legitimacy into commercialization to avoid an industry-wide crisis.
October 23, 2020
Efforts to address prescription drug pricing have expanded. Rick Kelly reports.
September 27, 2020
Even advocates of U.S. drug pricing reform recognize that President Trump's revised initiative to reduce the price of prescription drugs is unlikely to save money for consumers or the government.
September 13, 2020
President Trump has taken on the pharma industry in a surprise move making significant cuts in reimbursement for drugs covered by Medicare.